Examine the role of biosimilars indicated for IBD in the reduction of healthcare costs and improvement of patient access to care Address common misconceptions about biosimilar development, manufacturing, and the regulatory approval processes Evaluate the latest clinical data on current and emerging biosimilars for IBD, including their efficacy/safety profiles and routes of administration Apply strategies to mitigate barriers to biosimilar use, with an emphasis on educational efforts, understanding FDA updates on interchangeability, and resolving access issues
- Provider:HMP Education
- Activity Link: https://hmpeducation.com/program/24-aibd-204
- Start Date: 2025-01-11 06:00:00
- End Date: 2025-01-11 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABS - 0.5 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Limited
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest